Size | Price | Stock | Qty |
---|---|---|---|
10mg |
|
||
25mg |
|
||
50mg |
|
||
100mg |
|
||
Other Sizes |
|
Targets |
GPR35 ( IC50 = 20.1 nM ); GPR55 ( EC50 = 21.7 μM )
|
---|---|
ln Vitro |
ML 145 (10 μM) completely prevents human FLAG-GPR35-eYFP from internalizing in response to different dosages of zaprinast, cromolyn disodium, and pomoate in addition[2].
ML 145 either has no effect (mouse) or exhibits a negligible, seemingly noncompetitive inhibitory effect (rat) at the rodent orthologs[2]. ML 145 functions as a competitive antagonist for several agonists at human GPR35 and has an IC50 value of about 20 nM against the EC80 concentrations of different GPR35 agonists[1]. |
References |
Molecular Formula |
C24H22N2O5S2
|
---|---|
Molecular Weight |
482.571883678436
|
Exact Mass |
482.097
|
Elemental Analysis |
C, 59.74; H, 4.60; N, 5.81; O, 16.58; S, 13.29
|
CAS # |
1164500-72-4
|
PubChem CID |
2286812
|
Appearance |
Yellow to brown solid powder
|
Density |
1.5±0.1 g/cm3
|
Index of Refraction |
1.719
|
LogP |
4.38
|
Hydrogen Bond Donor Count |
3
|
Hydrogen Bond Acceptor Count |
7
|
Rotatable Bond Count |
8
|
Heavy Atom Count |
33
|
Complexity |
835
|
Defined Atom Stereocenter Count |
0
|
SMILES |
C1=CC=C(/C=C(/C=C2\SC(=S)N(CCCC(NC3=CC=C(C(=O)O)C(O)=C3)=O)C\2=O)\C)C=C1
|
InChi Key |
COFMYJWNXSFLKQ-QIROLCGISA-N
|
InChi Code |
InChI=1S/C24H22N2O5S2/c1-15(12-16-6-3-2-4-7-16)13-20-22(29)26(24(32)33-20)11-5-8-21(28)25-17-9-10-18(23(30)31)19(27)14-17/h2-4,6-7,9-10,12-14,27H,5,8,11H2,1H3,(H,25,28)(H,30,31)/b15-12+,20-13-
|
Chemical Name |
2-hydroxy-4-[4-[(5Z)-5-[(E)-2-methyl-3-phenylprop-2-enylidene]-4-oxo-2-sulfanylidene-1,3-thiazolidin-3-yl]butanoylamino]benzoic acid
|
Synonyms |
ML145; ML-145; ML 145
|
HS Tariff Code |
2934.99.9001
|
Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
Solubility (In Vitro) |
DMSO: ~50 mg/mL (~103.6 mM)
|
---|---|
Solubility (In Vivo) |
Solubility in Formulation 1: 5 mg/mL (10.36 mM) in 10% DMSO + 40% PEG300 +5% Tween-80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), suspension solution; with sonication.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 50.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 + to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution.  (Please use freshly prepared in vivo formulations for optimal results.) |
Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
1 mM | 2.0722 mL | 10.3612 mL | 20.7224 mL | |
5 mM | 0.4144 mL | 2.0722 mL | 4.1445 mL | |
10 mM | 0.2072 mL | 1.0361 mL | 2.0722 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
ML-145 is also a highly selective human GPR35 antagonist in β-arrestin-2 interaction assays. J Pharmacol Exp Ther . 2012 Dec;343(3):683-95. td> |
CID-2745687 and ML-145 both block agonist-mediated internalization of human but not rodent forms of GPR35. J Pharmacol Exp Ther . 2012 Dec;343(3):683-95. td> |
CID-2745687 and ML-145 block agonist-mediated internalization of human GPR35 in a concentration-dependent fashion. J Pharmacol Exp Ther . 2012 Dec;343(3):683-95. td> |
CID-2745687 and ML-145 block both constitutive and agonist-mediated IP1 accumulation only at the human ortholog of GPR35. J Pharmacol Exp Ther . 2012 Dec;343(3):683-95. td> |